cannabidiol/tetrahydrocannabinol (T2:C100) / MediPharm Labs, University of Southern California - LARVOL DELTA

LiBBY: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: University of Southern California | Active, not recruiting ➔ Completed | Trial completion date: Aug 2026 ➔ Apr 2026 | Trial primary completion date: Apr 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

LiBBY: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: University of Southern California | Trial completion date: Mar 2026 ➔ Aug 2026

Trial completion date • Alzheimer's Disease • CNS Disorders • Dementia

LiBBY: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: University of Southern California | Trial completion date: Dec 2025 ➔ Mar 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Alzheimer's Disease • CNS Disorders • Dementia

LiBBY: Life's End Benefits of Cannabidiol and Tetrahydrocannabinol (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: University of Southern California | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Dementia

LiBBY: Life's End Benefits of Cannabidiol and Tetrahydrocannabinol (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: University of Southern California

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia

LiBBY: Life's End Benefits of Cannabidiol and Tetrahydrocannabinol (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: University of Southern California | Initiation date: Jan 2023 ➔ Jun 2023

Trial initiation date • Alzheimer's Disease • CNS Disorders • Dementia